Faron Pharmaceuticals Oy FARN.L · Stock Open Faron Pharmaceuticals Oy in new tab
Faron Pharmaceuticals Oy Analysis (FARN.L)
Is Faron Pharmaceuticals Oy a good investment? Faron Pharmaceuticals Oy (FARN.L) is currently trading at 45.40 GBX.
Earnings Schedule: Faron Pharmaceuticals Oy is expected to release its next earnings report on March 19, 2027. The market consensus estimate for Forward EPS is -0.09.
Investor FAQ
Does Faron Pharmaceuticals Oy pay a dividend?
No, it does not currently pay a dividend.
What asset class is Faron Pharmaceuticals Oy?
Faron Pharmaceuticals Oy is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be March 19, 2027. The company currently has a trailing EPS of -0.19.
Company Profile
Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. The company's lead product candidate is Bexmarilimab, a novel anti-Clever-1 humanized antibody that targets a subpopulation of tumor-associated macrophages and converts the highly immunosuppressive M2-like macrophages to a pro-inflammatory state to promote immune activation. It is also developing bexmarilimab for the treatment of hematological and solid tumor cancers; and in combination with care therapies, azacitidine, and other hypomethylating agents in relapsed/refractory myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia. In addition, the company develops receptors involved in regulation of immune response in organ damage and bone marrow regeneration. Faron Pharmaceuticals Oy was founded in 2003 and is headquartered in Turku, Finland.
| Split Date | Split Ratio to 1 |
|---|---|
| June 4, 2024 | 1.21 |
Community Discussion